Abstract:Protein kinases (PKs) are involved in many intracellular signal transduction pathways through phosphorylation cascades and have become intensely investigated pharmaceutical targets over the past two decades. Inhibition of PKs using small-molecular inhibitors is a premier strategy for the treatment of diseases in different therapeutic areas that are caused by uncontrolled PK-mediated phosphorylation and aberrant signaling. Most PK inhibitors (PKIs) are directed against the ATP cofactor binding site that is largely conserved across the human kinome comprising 518 wild-type PKs (and many mutant forms). Hence, these PKIs often have varying degrees of multi-PK activity (promiscuity) that is also influenced by factors such as single-site mutations in the cofactor binding region, compound binding kinetics, and residence times. The promiscuity of PKIs is often—but not always—critically important for therapeutic efficacy through polypharmacology. Various in vitro and in vivo studies have also indicated that PKIs have the potential of interacting with additional targets other than PKs, and different secondary cellular targets of individual PKIs have been identified on a case-by-case basis. Given the strong interest in PKs as drug targets, a wealth of PKIs from medicinal chemistry and their activity data from many assays and biological screens have become publicly available over the years. On the basis of these data, for the first time, we conducted a systematic search for non-PK targets of PKIs across the human kinome. Starting from a pool of more than 155,000 curated human PKIs, our large-scale analysis confirmed secondary targets from diverse protein classes for 447 PKIs on the basis of high-confidence activity data. These PKIs were active against 390 human PKs, covering all kinase groups of the kinome and 210 non-PK targets, which included other popular pharmaceutical targets as well as currently unclassified proteins. The target distribution and promiscuity of the 447 PKIs were determined, and different interaction profiles with PK and non-PK targets were identified. As a part of our study, the collection of PKIs with activity against non-PK targets and the associated information are made freely available.

Putative role of natural products as Protein Kinase C modulator in different disease conditions

Protein kinase C inhibitors: a patent review (2010 - present)

Protein kinase inhibitors in the management of cancer: therapeutic opportunities from natural compounds

Small Molecule Modulators Targeting Protein Kinase CK1 and CK2

Kinase inhibitors: 20 years of success and many new challenges and recent trends in their patents

The role of natural products as PCSK9 modulators: A review

Natural products are an important source for proteasome regulating agents

Protein kinase CK2: a potential therapeutic target for diverse human diseases

Protein Kinases C-Mediated Regulations of Drug Transporter Activity, Localization and Expression

Targeting Protein Kinase C for Cancer Therapy.

Comprehensive Data-Driven Assessment of Non-Kinase Targets of Inhibitors of the Human Kinome

Natural Products and Traditional Medicine: Investigating the Role of Natural Products and Traditional Medicine in Modern Pharmacology

Protein kinases as therapeutic targets to develop anticancer drugs with natural alkaloids

Natural products: A potential immunomodulators against inflammatory-related diseases

Protein Kinase Inhibitor Peptide As a Tool to Specifically Inhibit Protein Kinase A

Dysregulation of lipid metabolism in chronic kidney disease and the role of natural products

Exploring New Potential Pkcθ Inhibitors Using Pharmacophore Modeling, Molecular Docking Analysis, and Molecular Dynamics Simulations

Potential role for protein kinase D inhibitors in prostate cancer

GPCR-Mediated Natural Products and Compounds: Potential Therapeutic Targets for the Treatment of Neurological Diseases

Progress in phosphorylation of natural products

Natural products and derivatives in renal, urothelial and testicular cancers: targeting signaling pathways and therapeutic potential